Analysts rate Applied DNA Sciences-APDN Stock (APDN:NSD) with an Hold rating

Based on the Applied DNA Sciences Stock Forecast from 1 analyst, the average analyst APDN stock price target is USD 6.00 over the next 12 months. Applied DNA Sciences Inc’s average analyst rating is Hold. Stock Target Advisor’s own stock analysis of APDN stock forecast is Bearish, which is based on 1 positive signal and 6 negative signals. At the last closing, Applied DNA Sciences stock price was USD 2.73Applied DNA Sciences stock price has changed by +1.28% over the past week, -0.14% over the past month and -51.16% over the last year.

 

About Applied DNA Sciences Inc. (APDN:NSD):

Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

 

What we like:

High Gross Profit to Asset Ratio

APDN stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

 

What we don’t like:

Low market capitalization

APDN stock is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for APDN stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

APDN stock price is trading high compared to its peers median on a price to book value basis.

Negative cashflow

Applied DNA Sciences had negative total cash flow in the most recent four quarters.

Negative free cash flow

Applied DNA Sciences had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

APDN stock has shown below median revenue growth in the previous 5 years compared to its sector.